Lilly Asia Ventures co-leads $100M+ round for Chinese biotech and its late-stage lupus drug
Can a Chinese biotech deliver the first new lupus drug in decades? A high-profile group of VCs are betting on it.
Lilly Asia Ventures and Lake Bleu Capital are the co-headliners for RemeGen’s latest raise, which brought in more than $100 million. Hudson Bay Capital and Vivo Capital — which, like LAV, also invested in a pre-IPO round for Legend Biotech unveiled today — chimed in, as did Janchor Partners and OrbiMed.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.